LncRNA Taurine Upregulated Gene 1 as a Potential Biomarker in the Clinicopathology and Prognosis of Multiple Malignant Tumors: A Meta-Analysis

Table 2

Subgroup analysis of the pooled HRs of OS with overexpressed lncRNA TUG1 in patients with cancer.

Stratified analysis	Number of cohorts	Number of patients	Pooled HR (95% CI)	value	Heterogeneity
					(%)	value
Origin
China	48	4272	1.93 (1.59-2.30)	<0.001	88.3	<0.001
Non-China	13	4133	1.27 (1.05-1.54)	0.013	76.6	<0.001
Cancer type
Head and neck neoplasms	5	525	0.83 (0.35-2.01)	0.687	90.3	<0.001
Respiratory tumor	5	525	0.50 (0.36-0.70)	<0.001	35.5	0.185
Gastrointestinal cancer	21	2650	2.12 (1.69-2.67)	<0.001	82.2	<0.001
Urinary tumor	11	1432	1.89 (1.27-2.79)	0.002	87.4	<0.001
Gynecologic tumor	8	1662	2.01 (1.40-2.89)	<0.001	76.5	<0.001
Hematological tumor	5	639	2.44 (1.87-3.18)	<0.001	0	0.587
Osteosarcoma	4	473	1.58 (1.16-2.14)	0.003	50.2	0.110
Melanoma	2	499	1.65 (0.80-3.38)	0.174	88.3	0.003
Number of patients
<100	37	2256	2.12 (1.72-2.63)	0.007	88.3	<0.001
≥100	24	6149	1.31 (1.08-1.60)	<0.001	84.1	<0.001
Detection method
qRT-PCR	50	4644	1.88 (1.57-2.25)	<0.001	88.0	<0.001
RNA-seq	11	4109	1.29 (1.07-1.57)	0.009	76.7	<0.001